IDx is the only company named to CB Insights Digital Health 150 with an FDA-cleared autonomous AI diagnostic
November 4, 2019
New York, NY, October 3, 2019 – Yesterday CB Insights announced that IDx was named to its inaugural Digital Health 150, a list of the most promising private digital health companies in the world. Of the 150 companies on the list that span a wide spectrum of categories, IDx Technologies holds the distinction as the only company with FDA clearance for an autonomous AI diagnostic system.
CB Insights identified one of the common themes across the selected companies is the use of artificial intelligence and machine learning to develop software platforms. What makes IDx unique is that the company focuses on autonomous AI. In 2018, IDx became the first and only company to receive FDA clearance for an autonomous AI system in any field of medicine. The AI system is called IDx-DR and enables primary care physicians to detect diabetic retinopathy, a leading cause of blindness, in real time, in their clinic, without an eye care specialist.
“There is a significant difference between assistive AI – which guides or assists a physician and where the ultimate clinical decision is in their hands – and autonomous AI – which makes an independent clinical decision that can be relied on without the input of a physician,” said Michael Abramoff, MD, PhD, Founder and CEO of IDx. “Autonomous AI has far greater potential to transform healthcare delivery. It increases healthcare productivity and lowers costs by freeing physicians from routine tasks. So far, we are the only company that has been able to prove autonomous AI can be done safely, effectively, and equitably.”
At the CB Insights Future of Health event yesterday, Abramoff explained how many healthcare systems have successfully implemented IDx-DR and integrated it into the patient workflow in order to deliver better comprehensive diabetes care and improve patient outcomes.
Earlier this year, IDx was also named to CB Insights AI 100 list.